Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. International Journal of Food Science and Technology. Epilepsy Behav.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 24, 2021

Using a content analysis approach, we investigated articles about medicinal cannabis from 2000 to the end of 2019 in the Medical Journal of Australia, Australian Doctor , Medical Observer , Australian Journal of General Practice , Australian Family Physicia n , and Australian Medicine. Refractory paediatric epilepsy. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

SEPTEMBER 23, 2019

The regulatory environment surrounding cannabis, medical and recreational marijuana, and cannabidiol (CBD) is rapidly changing, along with the retail environment. In 2015, Whiting, et al, performed a meta-analysis and systematic review of research on the medical use of cannabis. Hemp & cannabidiol: what is a medicine?

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73